Literature DB >> 21709220

Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation.

Sebastien Apcher1, Chrysoula Daskalogianni, Fabrice Lejeune, Bénédicte Manoury, Gabriela Imhoos, Lea Heslop, Robin Fåhraeus.   

Abstract

The MHC class I antigen presentation pathway allows the immune system to distinguish between self and nonself. Despite extensive research on the processing of antigenic peptides, little is known about their origin. Here, we show that mRNAs carrying premature stop codons that prevent the production of full-length proteins via the nonsense-mediated decay pathway still produce a majority of peptide substrates for the MHC class I pathway by a noncanonical mRNA translation process. Blocking the interaction of the translation initiation factor eIF4E with the cap structure suppresses the synthesis of full-length proteins but has only a limited effect on the production of antigenic peptides. These results reveal an essential cell biological function for a class of translation products derived during the pioneer round of mRNA translation and will have important implications for understanding how the immune system detects cells harboring pathogens and generates tolerance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21709220      PMCID: PMC3136330          DOI: 10.1073/pnas.1104104108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum.

Authors:  Thomas Serwold; Federico Gonzalez; Jennifer Kim; Richard Jacob; Nilabh Shastri
Journal:  Nature       Date:  2002-10-03       Impact factor: 49.962

2.  Constitutive display of cryptic translation products by MHC class I molecules.

Authors:  Susan R Schwab; Katy C Li; Chulho Kang; Nilabh Shastri
Journal:  Science       Date:  2003-09-05       Impact factor: 47.728

3.  Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1.

Authors:  Yili Yin; Bénédicte Manoury; Robin Fåhraeus
Journal:  Science       Date:  2003-09-05       Impact factor: 47.728

Review 4.  Post-proteasomal antigen processing for major histocompatibility complex class I presentation.

Authors:  Kenneth L Rock; Ian A York; Alfred L Goldberg
Journal:  Nat Immunol       Date:  2004-07       Impact factor: 25.606

5.  Translation initiation at non-AUG triplets in mammalian cells.

Authors:  D S Peabody
Journal:  J Biol Chem       Date:  1989-03-25       Impact factor: 5.157

Review 6.  eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation.

Authors:  A C Gingras; B Raught; N Sonenberg
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

7.  eIF4G is required for the pioneer round of translation in mammalian cells.

Authors:  Fabrice Lejeune; Aparna C Ranganathan; Lynne E Maquat
Journal:  Nat Struct Mol Biol       Date:  2004-09-07       Impact factor: 15.369

8.  The eukaryotic translation initiation factor 4GI is cleaved by different retroviral proteases.

Authors:  Enrique Alvarez; Luis Menéndez-Arias; Luis Carrasco
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

9.  Intron function in the nonsense-mediated decay of beta-globin mRNA: indications that pre-mRNA splicing in the nucleus can influence mRNA translation in the cytoplasm.

Authors:  J Zhang; X Sun; Y Qian; L E Maquat
Journal:  RNA       Date:  1998-07       Impact factor: 4.942

Review 10.  Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII.

Authors:  Peter M Kloetzel
Journal:  Nat Immunol       Date:  2004-07       Impact factor: 31.250

View more
  70 in total

Review 1.  Towards a systems understanding of MHC class I and MHC class II antigen presentation.

Authors:  Jacques Neefjes; Marlieke L M Jongsma; Petra Paul; Oddmund Bakke
Journal:  Nat Rev Immunol       Date:  2011-11-11       Impact factor: 53.106

Review 2.  DRiPs solidify: progress in understanding endogenous MHC class I antigen processing.

Authors:  Jonathan W Yewdell
Journal:  Trends Immunol       Date:  2011-09-29       Impact factor: 16.687

3.  Nuclear translation for immunosurveillance.

Authors:  Jonathan W Yewdell; Alexandre David
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-18       Impact factor: 11.205

4.  Translation of pre-spliced RNAs in the nuclear compartment generates peptides for the MHC class I pathway.

Authors:  Sébastien Apcher; Guy Millot; Chrysoula Daskalogianni; Alexander Scherl; Bénédicte Manoury; Robin Fåhraeus
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-30       Impact factor: 11.205

5.  Antigenic peptides: Reviving nuclear translation.

Authors:  Petra Van Damme; Gerben Menschaert
Journal:  Nat Chem Biol       Date:  2013-12       Impact factor: 15.040

6.  Substrate-induced protein stabilization reveals a predominant contribution from mature proteins to peptides presented on MHC class I.

Authors:  Jeff D Colbert; Diego J Farfán-Arribas; Kenneth L Rock
Journal:  J Immunol       Date:  2013-10-30       Impact factor: 5.422

Review 7.  A critical analysis of codon optimization in human therapeutics.

Authors:  Vincent P Mauro; Stephen A Chappell
Journal:  Trends Mol Med       Date:  2014-09-25       Impact factor: 11.951

Review 8.  Re-examining class-I presentation and the DRiP hypothesis.

Authors:  Kenneth L Rock; Diego J Farfán-Arribas; Jeff D Colbert; Alfred L Goldberg
Journal:  Trends Immunol       Date:  2014-02-21       Impact factor: 16.687

Review 9.  Lymphocyte repertoire selection and intracellular self/non-self-discrimination: historical overview.

Authors:  Donald R Forsdyke
Journal:  Immunol Cell Biol       Date:  2014-11-11       Impact factor: 5.126

10.  Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance.

Authors:  Jiajie Wei; Rigel J Kishton; Matthew Angel; Crystal S Conn; Nicole Dalla-Venezia; Virginie Marcel; Anne Vincent; Frédéric Catez; Sabrina Ferré; Lilia Ayadi; Virginie Marchand; Devin Dersh; James S Gibbs; Ivaylo P Ivanov; Nathan Fridlyand; Yohann Couté; Jean-Jacques Diaz; Shu-Bing Qian; Louis M Staudt; Nicholas P Restifo; Jonathan W Yewdell
Journal:  Mol Cell       Date:  2019-01-31       Impact factor: 17.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.